Literature DB >> 1370558

Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120.

M S Fung1, C R Sun, W L Gordon, R S Liou, T W Chang, W N Sun, E S Daar, D D Ho.   

Abstract

Two monoclonal antibodies designated BAT085 and G3-136 were raised by immunizing BALB/c mice with gp120 purified from human immunodeficiency virus type 1 (HIV-1) IIIB-infected H9 cell extracts. Among three HIV-1 laboratory isolates (IIIB, MN, and RF), BAT085 neutralized only IIIB infection of CEM-SS cells, whereas G3-136 neutralized both IIIB and RF. These antibodies also neutralized a few primary HIV-1 isolates in the infection of activated human peripheral blood mononuclear cells. In indirect immunofluorescence assays, BAT085 bound to H9 cells infected with IIIB or MN, while G3-136 bound to H9 cells infected with IIIB or RF, but not MN. Using sequence-overlapping synthetic peptides of HIV-1 IIIB gp120, the binding site of BAT085 and G3-136 was mapped to a peptidic segment in the V2 region (amino acid residues 169 to 183). The binding of these antibodies to immobilized gp120 was not inhibited by the antibodies directed to the principal neutralization determinant in the V3 region or to the CD4-binding domain of gp120. In a competition enzyme-linked immunosorbent assay, soluble CD4 inhibited G3-136 but not BAT085 from binding to gp120. Deglycosylation of gp120 by endo-beta-N-acetylglucosaminidase H or reduction of gp120 by dithiothreitol diminished its reactivity with G3-136 but not with BAT085. These results indicate that the V2 region of gp120 contains multiple neutralization determinants recognized by antibodies in both a conformation-dependent and -independent manner.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370558      PMCID: PMC240785     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding.

Authors:  U Olshevsky; E Helseth; C Furman; J Li; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

2.  Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4.

Authors:  J P Moore
Journal:  AIDS       Date:  1990-04       Impact factor: 4.177

3.  High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.

Authors:  E S Daar; X L Li; T Moudgil; D D Ho
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

4.  Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization.

Authors:  J E Hansen; H Clausen; C Nielsen; L S Teglbjaerg; L L Hansen; C M Nielsen; E Dabelsteen; L Mathiesen; S I Hakomori; J O Nielsen
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

5.  Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody.

Authors:  D D Ho; M S Fung; Y Z Cao; X L Li; C Sun; T W Chang; N C Sun
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

6.  Neutralizing antibodies and the course of HIV-induced disease.

Authors:  I Wendler; U Bienzle; G Hunsmann
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

7.  Temporal development of cross-neutralization between HTLV-III B and HTLV-III RF in experimentally infected chimpanzees.

Authors:  J Goudsmit; C Thiriart; L Smit; C Bruck; C J Gibbs
Journal:  Vaccine       Date:  1988-06       Impact factor: 3.641

8.  Effects on CD4 binding of anti-peptide sera to the fourth and fifth conserved domains of HIV-1 gp120.

Authors:  B Ardman; M Kowalski; J Bristol; W Haseltine; J Sodroski
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

9.  Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees.

Authors:  P L Nara; L Smit; N Dunlop; W Hatch; M Merges; D Waters; J Kelliher; R C Gallo; P J Fischinger; J Goudsmit
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

10.  Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies.

Authors:  P L Nara; W G Robey; S W Pyle; W C Hatch; N M Dunlop; J W Bess; J C Kelliher; L O Arthur; P J Fischinger
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

View more
  84 in total

1.  Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.

Authors:  A L Edinger; M Ahuja; T Sung; K C Baxter; B Haggarty; R W Doms; J A Hoxie
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.

Authors:  Ralph Pantophlet; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

3.  Enhancement of human immunodeficiency virus type 1 envelope-mediated fusion by a CD4-gp120 complex-specific monoclonal antibody.

Authors:  S Lee; K Peden; D S Dimitrov; C C Broder; J Manischewitz; G Denisova; J M Gershoni; H Golding
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 4.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

5.  Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation.

Authors:  A C Andeweg; P Leeflang; A D Osterhaus; M L Bosch
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

6.  Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection.

Authors:  Rong Rong; Frederic Bibollet-Ruche; Joseph Mulenga; Susan Allen; Jerry L Blackwell; Cynthia A Derdeyn
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

7.  Identification of functional regions in the human T-cell leukemia virus type I SU glycoprotein.

Authors:  L Delamarre; C Pique; D Pham; T Tursz; M C Dokhélar
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

8.  Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.

Authors:  R Wyatt; J Moore; M Accola; E Desjardin; J Robinson; J Sodroski
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

9.  In vivo distribution and cytopathology of variants of human immunodeficiency virus type 1 showing restricted sequence variability in the V3 loop.

Authors:  Y K Donaldson; J E Bell; E C Holmes; E S Hughes; H K Brown; P Simmonds
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

10.  Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection.

Authors:  L Q Zhang; P MacKenzie; A Cleland; E C Holmes; A J Brown; P Simmonds
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.